Stay updated with breaking news from Daptorum Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
02.03.2023 - Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the exciting ... Seite 1
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology
Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today... | February 6, 2023
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (the "Company") a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune